These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 22759759)

  • 1. Tigecycline as a therapeutic option in Stenotrophomonas maltophilia infections.
    Tekçe YT; Erbay A; Cabadak H; Sen S
    J Chemother; 2012 Jun; 24(3):150-4. PubMed ID: 22759759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Doxycycline or Minocycline to Sulfamethoxazole-Trimethoprim for Treatment of
    Alhayani T; Philpott CD; Liao S; Gentene AJ; Mueller EW
    Ann Pharmacother; 2024 Jan; 58(1):21-27. PubMed ID: 37125743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of Potential Alternative Treatment Agents for Stenotrophomonas maltophilia Isolates Nonsusceptible to Levofloxacin and/or Trimethoprim-Sulfamethoxazole.
    Biagi M; Tan X; Wu T; Jurkovic M; Vialichka A; Meyer K; Mendes RE; Wenzler E
    J Clin Microbiol; 2020 Jan; 58(2):. PubMed ID: 31748318
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical characteristics of Stenotrophomonas maltophilia meningitis in adults: a high incidence in patients with a postneurosurgical state, long hospital staying and antibiotic use.
    Huang CR; Chen SF; Tsai NW; Chang CC; Lu CH; Chuang YC; Chien CC; Chang WN
    Clin Neurol Neurosurg; 2013 Sep; 115(9):1709-15. PubMed ID: 23611735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monotherapy with minocycline or trimethoprim/sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections.
    Hand E; Davis H; Kim T; Duhon B
    J Antimicrob Chemother; 2016 Apr; 71(4):1071-5. PubMed ID: 26801080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes of Stenotrophomonas maltophilia infection treated with trimethoprim/sulfamethoxazole, minocycline, or fluoroquinolone monotherapy.
    Junco SJ; Bowman MC; Turner RB
    Int J Antimicrob Agents; 2021 Aug; 58(2):106367. PubMed ID: 34058337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Monte Carlo pharmacokinetic/pharmacodynamic simulation to evaluate the efficacy of minocycline, tigecycline, moxifloxacin, and levofloxacin in the treatment of hospital-acquired pneumonia caused by Stenotrophomonas maltophilia.
    Wei C; Ni W; Cai X; Cui J
    Infect Dis (Lond); 2015; 47(12):846-51. PubMed ID: 26167850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparisons between patients with trimethoprim-sulfamethoxazole-susceptible and trimethoprim-sulfamethoxazole-resistant Stenotrophomonas maltophilia monomicrobial bacteremia: A 10-year retrospective study.
    Wang CH; Lin JC; Lin HA; Chang FY; Wang NC; Chiu SK; Lin TY; Yang YS; Kan LP; Yang CH; Chan MC; Yeh KM
    J Microbiol Immunol Infect; 2016 Jun; 49(3):378-86. PubMed ID: 25081988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999).
    Gales AC; Jones RN; Forward KR; Liñares J; Sader HS; Verhoef J
    Clin Infect Dis; 2001 May; 32 Suppl 2():S104-13. PubMed ID: 11320451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Trimethoprim/Sulfamethoxazole (SXT), Minocycline, Tigecycline, Moxifloxacin, and Ceftazidime Alone and in Combinations for SXT-Susceptible and SXT-Resistant Stenotrophomonas maltophilia by In Vitro Time-Kill Experiments.
    Wei C; Ni W; Cai X; Zhao J; Cui J
    PLoS One; 2016; 11(3):e0152132. PubMed ID: 26999818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro combination of tigecycline with other antibiotics in Stenotrophomonas maltophilia isolates.
    Karamanlıoğlu D; Dizbay M
    Turk J Med Sci; 2019 Apr; 49(2):683-686. PubMed ID: 30866602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter surveillance of antimicrobial resistance on Stenotrophomonas maltophilia in Taiwan.
    Wu H; Wang JT; Shiau YR; Wang HY; Lauderdale TL; Chang SC;
    J Microbiol Immunol Infect; 2012 Apr; 45(2):120-6. PubMed ID: 22154599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections.
    Farrell DJ; Sader HS; Jones RN
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2735-7. PubMed ID: 20368399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro susceptibilities of Stenotrophomonas maltophilia isolates to antimicrobial agents commonly used for related infections: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2004-2020.
    Lee YL; Liu CE; Ko WC; Hsueh PR
    Int J Antimicrob Agents; 2023 Aug; 62(2):106878. PubMed ID: 37285926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levofloxacin-resistant Stenotrophomonas maltophilia: risk factors and antibiotic susceptibility patterns in hospitalized patients.
    Wang CH; Yu CM; Hsu ST; Wu RX
    J Hosp Infect; 2020 Jan; 104(1):46-52. PubMed ID: 31505224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of Cefiderocol Alone and in Combination with Levofloxacin, Minocycline, Polymyxin B, or Trimethoprim-Sulfamethoxazole against Multidrug-Resistant Stenotrophomonas maltophilia.
    Biagi M; Vialichka A; Jurkovic M; Wu T; Shajee A; Lee M; Patel S; Mendes RE; Wenzler E
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32571820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for infections with multidrug-resistant Stenotrophomonas maltophilia in patients with cancer.
    Ansari SR; Hanna H; Hachem R; Jiang Y; Rolston K; Raad I
    Cancer; 2007 Jun; 109(12):2615-22. PubMed ID: 17487860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluoroquinolones versus trimethoprim-sulfamethoxazole for the treatment of Stenotrophomonas maltophilia infections: a systematic review and meta-analysis.
    Ko JH; Kang CI; Cornejo-Juárez P; Yeh KM; Wang CH; Cho SY; Gözel MG; Kim SH; Hsueh PR; Sekiya N; Matsumura Y; Lee DG; Cho SY; Shiratori S; Kim YJ; Chung DR; Peck KR
    Clin Microbiol Infect; 2019 May; 25(5):546-554. PubMed ID: 30448331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infection and colonization by Stenotrophomonas maltophilia: antimicrobial susceptibility and clinical background of strains isolated at a tertiary care centre in Hungary.
    Juhász E; Krizsán G; Lengyel G; Grósz G; Pongrácz J; Kristóf K
    Ann Clin Microbiol Antimicrob; 2014 Dec; 13():333. PubMed ID: 25551459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activities of antimicrobial combinations against clinical isolates of Stenotrophomonas maltophilia.
    Liaw SJ; Teng LJ; Hsueh PR; Ho SW; Luh KT
    J Formos Med Assoc; 2002 Jul; 101(7):495-501. PubMed ID: 12353342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.